Focus Stocks
Research Analyst's New Ratings ( CNX, STLD, PODD, DXCM )
Published on Tuesday, 17 January 2012 08:32 Written by Danny Miller
New York, January 17th (TradersHuddle.com) - Pre-market new initiations and ratings.
CONSOL Energy (NYSE:CNX) was initiated with a Buy at Deutsche Bank.
Steel Dynamics (NASDAQ:STLD) was initiated with a Buy at Deutsche Bank.
Insulet Corporation (NASDAQ:PODD) was initiated with a Buy and a target price of $24 at Brean Murray.
DexCom (NASDAQ:DXCM) was initiated with a Buy and a target price of $12.50 at Brean Murray.
Related Articles
- A 52 Week Low for CONSOL Energy
- Bull And Bear Cases For Coal
- Neutral Short Term Pattern on CONSOL Energy
- CONSOL Energy Earns Virginia Reclamation Award
- DexCom Inc. Reports First Quarter 2012 Financial Results
- CONSOL Energy Declares Regular Quarterly Dividend of $0.125 per Share
- Dexcom to Present at the Deutsche Bank 37th Annual Healthcare Conference
- CONSOL Energy Reports First Quarter Results; Blacksville and Buchanan Longwalls Scheduled for May 1 Re-Start
- Dexcom Schedules First Quarter 2012 Earnings Release and Conference Call for May 2, 2012
- Are the Bears Taking Control over CONSOL Energy?
Related Partner Headlines
- Steel Dynamics Inc Stock Downgraded (STLD) - TheStreet.com
- Consol Energy Inc Stock Downgraded (CNX) - TheStreet.com
- Consol Energy Stock To Go Ex-dividend Tomorrow (CNX) - TheStreet.com
- Consol Energy Inc (CNX): Today's Featured Metals & Mining Winner - TheStreet.com
- UPDATE: Dahlman Rose Reiterates Buy Rating, Lowers PT for Consol Energy - Benzinga
- Steel Dynamics Stock To Go Ex-dividend Tomorrow (STLD) - TheStreet.com
- UPDATE: Citigroup Lowers PT on CONSOL Energy to $40 - Benzinga
- Consol Energy: S&P Intraday Laggard - TheStreet.com
- CONSOL Energy Temporarily Idles Longwall Mining at Buchanan Mine - Benzinga
- UPDATE: Dahlman Rose Lowers Target to $44 on Consol Energy - Benzinga
Real Money Pro from TheStreet: Headlined by legendary hedge fund manager Doug Kass, our team of market technicians and professional traders hand you unique perspectives and breakthrough investment opportunities.
Access this exciting service -- Real Money Pro -- FREE, right now!
TradersHuddle Search
| Sponsored By: |
|
Stock Search: |
|
Site Search: Loading
|
Latest Partner Headlines
-
Status Quo Is Good for Germany - TheStreet.com -
A Greek Exit Would Cut Both Ways - TheStreet.com -
Juniper Networks Inc. (JNPR): Today's Featured Technology Loser - TheStreet.com -
Celgene Corporation (CELG): Today's Featured Health Care Loser - TheStreet.com -
Colgate-Palmolive Company (CL): Today's Featured Consumer Goods Loser - TheStreet.com -
Virgin Media Inc (VMED): Today's Featured Services Loser - TheStreet.com -
Red Hat Inc. (RHT): Today's Featured Computer Software & Services Loser - TheStreet.com -
Royal Dutch Shell PLC ADR (RDS.B): Today's Featured Basic Materials Loser - TheStreet.com
Stock Market
Loading
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:12,496.15 Trade time:4:05PM EDT Value change:▼6.66 (-0.05%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,318.86 Trade time:4:33PM EDT Value change:▲2.23 (0.17%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:2,850.12 Trade time:5:16PM EDT Value change:▲11.04 (0.39%)In The Wires
-
Every Day is Memorial Day for Bugles Across America -
SBS Entertainment, MegaTV and Puerto Rico Tourism Company Present "Encanto del Caribe" with Arthur Hanlon and friends from the San Cristobal Fort in San Juan, Puerto Rico today Wednesday, May 23, at 8pm (ET)- 7pm (CT) on MegaTV -
New York Mortgage Trust Arranges Long Term Financing Secured by Multifamily CMBS Assets -
Coastal to Present at 9th Annual Craig-Hallum Institutional Investor Conference -
Klahoose First Nation and Alterra Power Sign Agreement for Upper Toba Project -
Robert A. Iger, Chairman and Chief Executive Officer, The Walt Disney Company, To Speak at the Sanford C. Bernstein Annual Strategic Decisions Conference 2012 -
CME Group Inc. Announces Preliminary Results from its 2012 Annual Meeting of Shareholders -
HeartWare Announces Publication Of Results From U.S. Bridge-To-Transplant Clinical Trial









